Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)
This is an open label, phase II study evaluating the efficacy and safety of trastuzumab combined with oral chemotherapy (capecitabine or vinorelbine) in patients with HER-2 positive stage I breast cancer.
Breast Cancer
DRUG: capecitabine and trastuzumab|DRUG: vinorelbine and trastuzumab
iDFS, iDFS invasive disease-free survival, 5 years
DDFS, distant disease-free survival, 5 years|OS, overall survival, 5 years
This is an open label, phase II study evaluating the efficacy and safety of trastuzumab combined with oral chemotherapy (capecitabine or vinorelbine) in patients with HER-2 positive stage I breast cancer.